

ORIGINAL PAPERS

# Transcultural adaptation and validation of the “Adult Eosinophilic Esophagitis Quality of Life Questionnaire” into Spanish

Alfredo J. Lucendo<sup>1</sup>, Marta Sánchez-Cazalilla<sup>1,2</sup>, Javier Molina-Infante<sup>3</sup>, Isabel Pérez-Martínez<sup>4</sup>, José M. Tenias<sup>5</sup>, Jesús Barrio<sup>6</sup>, Óscar Nantes<sup>7</sup>, Constanza Ciriza de los Ríos<sup>8</sup>, Antonia Perelló<sup>9</sup> and Ángel Arias<sup>5</sup>

<sup>1</sup>Department of Gastroenterology. Hospital General de Tomelloso. Tomelloso, Ciudad Real. Spain. <sup>2</sup>Department of Gastroenterology. Clínica Ruber. Madrid, Spain. <sup>3</sup>Department of Gastroenterology. Hospital San Pedro de Alcántara. Cáceres, Spain. <sup>4</sup>Department of Gastroenterology. Hospital Universitario Central de Asturias. Oviedo, Spain. <sup>5</sup>Research Support Unit. Complejo Hospitalario La Mancha-Centro. Alcázar de San Juan, Ciudad Real. Spain. <sup>6</sup>Department of Gastroenterology. Hospital Universitario Río Hortega. Valladolid, Spain. <sup>7</sup>Department of Gastroenterology. Complejo Hospitalario de Navarra. Pamplona, Spain. <sup>8</sup>Department of Gastroenterology. Hospital Universitario 12 de Octubre. Madrid, Spain. <sup>9</sup>Department of Gastroenterology. Hospital de Viladecans. Barcelona, Spain

## ABSTRACT

**Background:** The “Adult Eosinophilic Esophagitis Quality of Life (EoE-QoL-A) Questionnaire” was developed in English as a valid, reliable, and disease-specific health-related QoL measure. This research aims to adapt and validate this questionnaire for Spanish-speaking patients.

**Patients and methods:** A multicenter, observational, prospective study was conducted at 8 Spanish hospitals. The cultural adaptation of the original EoE-QoL-A questionnaire was undertaken through a standardized 3-phase procedure: 1. Translation; 2. Retrotranslation; and 3. Pilot study. Patients completed the Hospital Anxiety and Depression Scale (HADS), the Short Form (SF)-12, the Brief Illness Perception Questionnaire (BIPQ), and the adapted EoE-QoL-A, with a retest 3 months later. Statistical analysis included construct validity, internal consistency, criterion validity, and reproducibility.

**Results:** One hundred and seventy adult EoE patients (73.5 % male; aged  $33.5 \pm 11.4$ -y) were included in the study. With regard to internal validity, all Cronbach alpha values were  $> 0.75$ . A significant correlation between items assessed in the SF-12, BIPQ and EoE-QoL-A questionnaires ( $p < 0.001$ ) was observed. Correlations with the HADS were stronger for anxiety than for depression levels. Anxiety related to disease diagnosis and choking were the most affected dimensions; less affected were the dimensions related to eating, social, and emotional development.

**Financial support:** This work has been supported by grants from the Spanish Society for Digestive Diseases (*Sociedad Española de Patología Digestiva* – SEPD) and from the Spanish Digestive System Foundation (*Fundación Española del Aparato Digestivo* – FEAD).

Received: 31-03-2014  
Accepted: 07-07-2014

**Correspondence:** Alfredo J. Lucendo. Department of Gastroenterology. Hospital General de Tomelloso. Vereda de Socuéllamos, s/n. 13700 Tomelloso, Ciudad Real. Spain  
e-mail: alucendo@vodafone.es

Intraclass correlation coefficients between the test and retest assessments were acceptable for all questionnaires, with the highest values (0.73-0.84) calculated for the EoE-QoL-A Spanish version.

**Conclusion:** The Spanish version of the EoE-QoL-A is a reliable, valid, and responsive questionnaire. Diagnosis and choking anxiety were the most affected dimensions in the health-related QoL in adult EoE patients.

**Key words:** Eosinophilic esophagitis. Quality of life. Questionnaire.

## INTRODUCTION

Eosinophilic esophagitis (EoE) is a chronic, food allergy-associated, inflammatory disease characterized clinically by symptoms related to esophageal dysfunction and histologically by an eosinophil-predominant inflammation that persists after treatment with acid secretion inhibitors (1). EoE, which lasts from childhood into adulthood (2), has exhibited a rapidly increasing epidemiology, with a prevalence in Europe and the USA ranging from 43 to 56 affected patients per 100,000 inhabitants (3-5). As a consequence, EoE now represents the second leading cause of chronic esophagitis after gastroesophageal reflux disease (GERD) (6) and is the most frequent cause of dysphagia in young patients (7).

Lucendo AJ, Sánchez-Cazalilla M, Molina-Infante J, Pérez-Martínez I, Tenias JM, Barrio J, Nantes O, Ciriza de los Ríos C, Perelló A, Arias A. Transcultural adaptation and validation of the “Adult Eosinophilic Esophagitis Quality of Life Questionnaire” into Spanish. *Rev Esp Enferm Dig* 2014;106:386-394.

In addition to the persistent or relapsing esophageal symptoms that characterize EoE, other factors have a significant impact on the health-related quality of life (QoL) of EoE patients. These factors include restrictions of common foods and other dietary modifications as well as the chronic nature of the disease (8-10), which requires continuous or repeated therapeutic interventions (11).

The evaluation of health-related QoL assesses the impact a given disease has on the patient's perception of his or her own welfare in physical, psychological, and social terms due to the decrease in opportunities caused either by the disease, its consequences and treatment, and/or pertinent health policies. Health-related QoL is a consistently evaluated, patient-reported outcome for chronic illnesses, including most gastrointestinal disorders (12-16). Questionnaires that are specifically designed for patients with a particular disease manage to combine patient perception of the qualitative indicators that influence QoL with objective biological data, thus providing valuable information for developing interventions to promote the greatest possible well-being as well as a better optimization of healthcare resources (17-19).

The adverse impact of EoE on patient QoL has been increasingly recognized over the past few years, especially after researchers documented that regular assessment of EoE, based mainly on the frequency and severity of dysphagia, did not adequately reflect the impact of the disease in psychological or social terms (20). Moreover, generic instruments assessing QoL generally failed to reflect many of the concerns and worries of EoE patients regarding their disease (21). Given the lack of specific tools for EoE, Taft et al. developed the Adult Eosinophilic Oesophagitis Quality of Life (EoE-QoL-A) Questionnaire for adult patients (22), which originally consisted of 37 items grouped into 5 categories (eating/diet impact, social impact, emotional impact, anxiety resulting from the disease, and anxiety generated by esophageal impaction). The questionnaire was validated in a sample of 201 adult patients and has repeatedly demonstrated its reliability and validity for correlation with other general scales of QoL.

The EoE-QoL-A questionnaire has yet to be validated in a language other than English or in a cultural context apart from that of American, so it has not been directly applicable in the Spanish language or cultural environment. The objective of this study was to adapt and validate the EoE-QoL-A questionnaire in Spanish in order to provide a useful instrument for assessing adult patients suffering from EoE.

## PATIENTS AND METHODS

This observational and prospective study was conducted at 8 different tertiary gastroenterology facilities located in several regions of Spain. The study protocol

comprised two different phases: Cultural adaptation and validation. Recruitment of participant patients was developed between January and December 2013. The study was approved by the institutional research ethics board of La Mancha-Centro General Hospital.

## Questionnaires

Initially, the EoE-QoL-A was a 37-item symptom inventory specifically for adult patients with EoE. Developed by Taft et al. at Northwestern's Feinberg School of Medicine in Chicago, IL (USA), it included symptoms of esophageal dysfunction, disease impact, and anxiety. A refined 30-item scale was later published by the same researchers (23).

The current questionnaire consists of 30 items categorized according to the original five dimensions. The impact of the disease on eating patterns and diet comprises 10 items (2, 9, 16, 24, 25, 26, 27, 28, 29, and 30), the social impact dimension consists of 4 items (14, 17, 19, and 22), and the emotional impact is measured with 8 items (1, 5, 6, 7, 11, 13, 21, and 23). In addition, disease anxiety is explored with 5 items (4, 10, 12, 15, and 18) while choking anxiety consists of 3 items (3, 8, and 20).

The Short Form (SF)-12 is a self-administered health-related QoL assessment instrument specifically designed for general population use. Validated for use in Spanish (24), it consists of twelve items, with physical and mental health separated into two distinct domains.

The BIPQ (Brief Illness Perception Questionnaire) was designed to facilitate rapid assessment of a patient's personal perception of his or her illness (25). The BIPQ consists of eight items related to illness perception, all rated on a 0-10 scale. It has recently been validated for use in Spanish by Pacheco-Huergo et al. (BIPQ<sub>v2</sub>) (26).

The Hospital Anxiety and Depression Scale (HADS) is a self-administered 14-item questionnaire composed of two intermingled 7-item subscales for anxiety and depression, excluding physical symptoms. A validated Spanish version of the HADS is also available (27).

## Linguistic validation

Translation of the original EoE-QoL-A into Spanish was carried out following a standardized forward-backward procedure: Two independent bilingual translators (with American English as their mother tongue) made forward translations while backward translations were made by two native-speakers of Spanish. The Spanish versions of the questionnaire were then tested in 10 adult patients with EoE, as defined according to the diagnostic criteria listed in the Updated International Consensus Guidelines for EoE (1). Potential problems were explored and discussed with the aid of a checklist. As a result, the lay-out

was adapted to clarify the instructions on how to indicate the chosen answer. The Spanish version of EoE-QoL-A questionnaire was then finalized (Appendix 1).

### Study population and study design

Male and female patients aged 18 years or older and with an established diagnosis of EoE according to the aforementioned criteria were recruited. All the study subjects were fluent and literate native speakers of Spanish. Exclusion criteria included significant changes in patient management during the research period or the presence of additional symptomatic upper gastrointestinal disorders, neurological diseases, active malignant tumors, dementia, or mental retardation.

At the initial office visit, the treating physician explained the study to all consecutive patients potentially eligible for inclusion. After hearing the explanation of the study and giving informed consent, participating patients were given a package including further written information regarding the study aims along with instructions on how to complete the set of questionnaires and a booklet including all four questionnaires. A telephone number and email address were also provided in case of further doubts.

Alternatively, a baseline set of questionnaires was completed at the hospital or at home and returned by post directly after completion.

Twelve weeks later, all subjects completed a second set of questionnaires which were returned to the testing center by post. The 12-week test-retest period between repeated administration of the questionnaires was chosen as being long enough to prevent recall bias, but short enough to ensure that meaningful clinical changes had not occurred. During this period, no treatment was initiated or modified. Given the observational nature of the study, the treating physician was free to perform any intervention (e.g., endoscopic evaluation, allergy tests, or analytical study) and prescribe any treatment only after completion of the second round of questionnaires, according to the needs of each patient.

### Statistical methods

Statistical analysis was performed with IBM SPSS-software 20.0 (SPSS Inc, Chicago, IL, USA). Statistical significance was defined as  $p$ -values  $< 0.05$ . Mean and standard deviations (SD) were reported for continuous data. For discrete data, counts and percentages were reported.

Measure properties of the Spanish version of the EoE-QoL-A questionnaire were tested as follows (28):

1. *Internal consistency*, that is, the extent to which items measure the same underlying construct, was

tested by calculating Cronbach alpha values using baseline scores. A Cronbach alpha value between 0.70 and 0.95 was considered to reflect good internal consistency.

2. *Reproducibility*, that is, the degree to which repeated measurements in the test-retest period provide similar answers, concerns reliability and agreement. Agreement, that is, the extent to which scores on repeated measures have similar values, was quantified with interclass correlation coefficients.
3. *Construct validity*, that is, the extent to which the scores relate to other measures, was verified by means of a factorial analysis to identify the constructs or dimensions of the EoE-QoL-A questionnaire. A confirmatory approach using a forcing decomposition of five factors through orthogonal rotations (uncorrelated factors) or oblique rotations, if necessary, was used to improve the interpretation of the dimensions.
4. *Criterion validity* was examined by calculating Spearman's correlation coefficient (Rho) between the Spanish versions of the EoE-QoL-A, HAD, SF-12 and BIPQ<sub>v2</sub> questionnaires.

## RESULTS

### Study subjects

One hundred and seventy adult patients diagnosed with EoE were consecutively recruited at 8 hospitals in Spain (Appendix 2), including 125 men (73.5 %) and 45 women (26.5 %) with a mean age of 33.5 years (SD: 11.4; rank 18 to 77.5). With regard to EoE treatment, 102 patients (60 %) had been prescribed some kind of dietary restriction. No differences were observed in the demographic data or EoE symptoms of patients with or without dietary-based therapeutic interventions (Table I).

A set of questionnaires was administered to and completed by each patient, who was then given an appointment to return to the hospital 3 months later. Of the initial 170 patients, 158 (92.94 %) completed the second set of questionnaires, including 115 men (72.8 %) and 43 women (27.2 %).

### Internal consistency of the Spanish version of EoE-QoL-A

Each dimension showed good internal consistency as determined by Cronbach's alpha values over 0.75; similar and consistent values were also observed at the retest visit 3 months later. The dimensions with the highest internal consistency were impact on eating/diet, followed by disease anxiety, choking anxiety, and social impact (Table II).

**Table I. Demographic and clinical characteristics of adult EoE patients recruited for our study**

Characteristics	All (n = 170)	Diet restriction (n = 102)	No diet restriction (n = 68)	p
Age (SD)	33.35 (11.4)	33.9 (10.6)	32.9 (12.7)	0.608
Gender (m/f)	125 (73.5%) / 45 (46.5%)	73 (71.6%) / 29 (28.4%)	76.5 (76.5%) / 16 (23.5%)	0.478
Symptoms	Food impaction	82 (80.4%)	51 (75%)	0.404
	Dysphagia	79 (75.5%)	52 (76.5%)	0.882
	Pyrosis	35 (34.3%)	28 (41.2%)	0.364
	Regurgitation	11 (10.8%)	11 (16.2%)	0.305
	Chest pain	14 (13.7%)	8 (11.8%)	0.709
	Vomiting	5 (4.9%)	1 (1.5%)	0.404

**Table II. Structure, impact, and internal consistency (Cronbach  $\alpha$  values) of the EoE QoL-A**

5-Factor structure	Items	Average impact	Cronbach $\alpha$
Eating/diet impact	2,9,16,24,25,26,27,28,29,30	2.53	0.91
Social impact	14,17,19,22	2.77	0.78
Emotional impact	1,5,6,7,11,13,21,23	2.15	0.91
Disease anxiety	4,10,12,15,18	3.13	0.85
Choking anxiety	3,8,20	2.97	0.78

With respect to the average impact for each dimension, disease anxiety was the highest, followed by choking anxiety, social impact, eating/diet impact and finally emotional impact (Table II). These results remained unchanged 3 months later (Fig. 1).

A significantly higher impact for two of the dimensions analyzed –eating/diet impact and emotional impact– was documented for adult patients following some type of dietary restriction compared to those who were not, with results of 2.79 vs. 2.13 ( $p < 0.001$ ) for the former dimension and 2.29 vs. 1.92 ( $p = 0.007$ ) for the latter (Table III).




Fig. 1. Average impact of the 5 dimensions in the Adult EoE Quality of Life (EoE-QoL-A) Questionnaire measured at base line and in the retest phase after 3 months.

**Table III. Average impact of EoE in patients undergoing some kind of dietary restriction compared with those who were not. Eating/diet impact and emotional impact were shown to be higher among patients following a diet-based therapeutic intervention**

5-Factor structure	Diet restriction average impact (SD)	No diet restriction average impact (SD)	p
Eating/diet impact	2.79 (0.9)	2.13 (0.9)	< 0.001
Social impact	2.86 (1.2)	2.70 (1.1)	0.394
Emotional impact	2.29 (0.9)	1.92 (0.8)	0.007
Disease anxiety	3.20 (1)	3.03 (0.9)	0.266
Choking anxiety	2.99 (1.1)	2.95 (1.1)	0.839



## Criterion validity

### HAD scale (anxiety and depression)

A probable or certain anxiety was observed in 31.1 % of patients, while 9.8 % of patients showed a probable or certain depression. These figures were similar for the second assessment (the retest phase), with results of 27.2 % and 8.4 %, respectively.

Statistically significant correlations (Spearman Rho) between the EoE-QoL-A and HAD questionnaires were documented for both anxiety and depression levels; however, anxiety levels demonstrated a stronger correlation than depression (Table IV). These results remained unchanged in the retest phase 3 months later.

### BIPQ<sub>v2</sub> (disease perception)

A pattern of relevant, meaningful, and consistent correlations between the EoE-QoL-A and BIPQ<sub>v2</sub> scales was demonstrated, relating disease perception and the impact of EoE (Table V). Disease impact (item 1), symptoms or discomfort from the disease (item 5), concern about the

disease (item 6) and how the disease affects the patient's own life (item 8) were the dimensions that best correlated with the five dimensions of the EoE-related QoL. In contrast, patient attitudes towards controlling the disease (item 3) and the usefulness of treatment (item 4) did not significantly correlate with any of the items on the EoE-QoL-A. Retest results after 3 months were similar.

### SF-12

The five dimensions of the EoE-QoL-A inversely and significantly correlated with mental health, vitality, overall health status, bodily pain, and physical functioning. In contrast, the emotional and social functioning scales did not correlate with the anxiety dimensions of the EoE-QoL-A and physical functioning only correlated weakly with choking anxiety (Table VI). These correlations were unchanged after 3 months.

### Test/retest reliability (intraclass correlation coefficients)

The retest results between administration of the first and second questionnaire in the series of 158 patients who completed two set of questionnaires were consistent. The intraclass correlation coefficients between the different questionnaires used during the first and second visits were acceptable, with the EoE-QoL-A questionnaire exhibiting the highest intraclass correlation coefficients (Table VII).

## DISCUSSION

This qualitative research has produced a Spanish version of the EoE-QoL-A questionnaire, which, after transcultural validation and adaptation, has proven to be a reli-

**Table IV. Criterion validity I: Spearman's correlation coefficient (Rho) between EoE-QoL-A and HAD questionnaires**

5-Factor structure	HAD (anxiety)	HAD (depression)
Eating/diet impact	0.319**	0.272**
Social impact	0.466**	0.383**
Emotional impact	0.476**	0.400**
Disease anxiety	0.431**	0.329**
Choking anxiety	0.421**	0.285**

\*\*p < 0.001.

**Table V. Criterion validity II: Spearman's correlation coefficient (Rho) between EoE-QoL-A and BIPQ questionnaires**

EoE-QoL-A	Eating/diet impact	Social impact	Emotional impact	Disease anxiety	Choking anxiety
BIPQ <sub>v2</sub>					
Consequences (item 1)	0.730**	0.439**	0.723**	0.582**	0.543**
Timeline (item 2)	0.190*	0.174*	0.117	0.121	0.109
Personal control (item 3)	0.116	-0.070	-0.104	-0.009	0.005
Treatment control (item 4)	0.050	-0.079	-0.165*	-0.096	-0.060
Identity (item 5)	0.436**	0.402**	0.551**	0.508**	0.468**
Concern (item 6)	0.547**	0.480**	0.582**	0.623**	0.544**
Understanding (item 7)	0.220**	-0.017	0.018	0.043	0.029
Emotional response (item 8)	0.613**	0.495**	0.783**	0.600**	0.568**

\* p < 0.05; \*\*p < 0.001.

**Table VI. Criterion validity III: Spearman's correlation coefficient (Rho) between EoE-QoL-A and SF12 questionnaires**

<i>SF12</i> \ <i>EoE-QoL-A</i>	<i>Eating/diet impact</i>	<i>Social impact</i>	<i>Emotional impact</i>	<i>Disease anxiety</i>	<i>Choking anxiety</i>
Physical functioning	-0.128	-0.108	-0.144	-0.114	-0.157(*)
Role physical	-0.265(**)	-0.182(*)	-0.346(**)	-0.198(*)	-0.268(**)
Bodily pain	-0.169(*)	-0.186(*)	-0.288(**)	-0.215(**)	-0.229(**)
General health	-0.302(**)	-0.217(**)	-0.374(**)	-0.272(**)	-0.214(**)
Vitality	-0.362(**)	-0.344(**)	-0.432(**)	-0.273(**)	-0.249(**)
Social functioning	-0.273(**)	-0.300(**)	-0.416(**)	-0.147	-0.149
Role emotional	-0.176(*)	-0.211(**)	-0.280(**)	-0.117	-0.146
Mental health	-0.352(**)	-0.261(**)	-0.373(**)	-0.240(**)	-0.263(**)

\*p &lt; 0.05; \*\*p &lt; 0.001.

able, valid, and responsive instrument for assessing health related QoL in adult men and women with EoE.

Chronic diseases such as EoE significantly impact the QoL of affected patients over and above the proper medical control that can be provided (which, in the case of EoE, aims for histological and symptomatic remission). Specific instruments for measuring QoL have demonstrated their usefulness as tools to provide insight into new dimensions of disease. In turn, the advantages gained from measuring health-related QoL have inspired the creation of new questionnaires adapted to different diseases. However, most questionnaires measuring QoL, including the EoE-QoL-A, were originally developed in English. Given the complexity of developing these questionnaires, their translation and validation into other languages and cultural environments has become a common strategy that further allows comparisons between patients of various cultural and linguistic backgrounds. For this reason, we have embarked upon this project to translate and validate the EoE-QoL-A questionnaire, which was originally developed in English for adult American EoE patients (22,23). Our research involved the translation, retro-translation, and understandability rating of the questionnaire; subsequently, the main psychometric properties of the Spanish version of the EoE-QoL-A questionnaire were analyzed for internal convergent and discriminant validity. By readministering the questionnaire to the same patients after a 3-month period during which no therapeutic changes were undertaken, we were able to analyze the questionnaire's stability and sensitivity to change.

The internal validity of the Spanish version of the EoE-QoL-A has been shown to adequately fulfill the properties of floor and ceiling effects –as well as those of feasibility and reliability– with very high Cronbach alpha values, obtained in both the first and second administration of the questionnaire to patients.

Since no previous questionnaire capable of assessing the health-related QoL of EoE patients was available, the con-

**Table VII. Test/retest reliability: Intraclass correlation coefficients of the different questionnaires used**

<i>Questionnaire</i>	<i>Intraclass correlation coefficient</i>
A-EoE-QoL	0.73-0.84
RF HAD	0.67-0.85
BIPQ <sub>v2</sub>	0.55-0.74
SF12	0.52-0.76

vergent validity of the Spanish version of the EoE-QoL-A questionnaire was analyzed through comparison with the SF-12 questionnaire, a generic tool already validated for use in Spanish and widely recognized and used in clinical practice. Another validated instrument was used to measure self-reported anxiety and depression (HAD scale) while perception of the disease was assessed with the aid of the validated BIPQ<sub>v2</sub> questionnaire. Correlation between the overall scores of the Spanish version of EoE-QoL-A and the remaining questionnaires was high and statistically significant, demonstrating the validity of our translated and adapted version.

Anxiety about the disease was the most affected dimension of the EoE-QoL-A questionnaire. This may reflect a lack of knowledge about the effectiveness of available EoE treatments, or it may be associated with the uncertainties associated with the onset of a relatively new and partially unknown disease, not only for patients, but also for many physicians. Caregivers can help alleviate some of these concerns by providing patients with accurate information about the disease, its prognosis, and the currently available treatment alternatives. The greatest concern expressed by patients was choking anxiety; indeed the fear of suffering a food impaction requiring endoscopic removal overwhelmingly led patients to adopt adaptive behaviors with regard to their social and eating habits. In order to alleviate this fear, providing patients with effective therapies capable of achieving sustained disease remission is of the utmost importance.

Interestingly, one of the least affected dimensions was the impact on eating/diet, although it was significantly more affected among patients following some type of dietary restriction, as was also the case with emotional impact of the disease. However, because the eating/diet impact dimension was also affected, albeit to a lesser extent, in patients on a regular diet, it is possible that this finding does not reflect the real quality of eating, but rather long-standing, normalized behavioral modifications, including food avoidance, food and/or consistency modification, and changes in eating pace. Emotional impact was the least affected dimension, which may reflect a reality in which dysphagia is not perceived as a troublesome symptom and does not impair the psychosocial development of the individual.

Transcultural validation studies for instruments that attempt to measure health-related QoL generally have several biases and limitations. On the one hand, the linguistic difficulties in finding semantic equivalents between the original and target language must be taken into account. To deal with this problem, we opted for a “free translation” of the original EoE-A-QoL questionnaire, more related to the sense and meaning of the expression than to strict linguistic correctness or syntax. Participating translators were able to contribute with their opinions and choose among several versions considered to be correct. The initial version of the questionnaire was also refined after a pilot test was conducted on a small number of EoE patients. Proof of correctness and equivalence between the two instruments was provided by the high internal consistency within the proposed/explored/found dimensions by the questionnaire designer and the almost identical factorial structure observed after applying an exploratory factorial analysis to our data.

Another common problem with questionnaires has to do with inconsistencies in the measurement of the constructs they are supposed to measure. To avoid this, new questionnaires are usually compared to other question-

naires that have already been validated in representative populations. In our work, we found a high degree of consistency between the responses to the EoE-A-QoL questionnaire and the dimensions and constructs of the SF12, HAD, and BIPQ<sub>v2</sub>.

Finally, another common problem with adapting this type of instrument has to do with the lack or excess of interpersonal and intrapersonal variability, which renders a questionnaire unsuitable and unstable. Fortunately, this was not the case for our Spanish version of the EoE-A-QoL questionnaire, which showed an acceptable variability among patients from several centers around the country, all at different stages of the disease. To date, the Spanish EoE-A-QoL questionnaire has also exhibited a good intra-patient variability, with equivalent and stable results after being administered a second time.

Still, it is possible that the Spanish version of the EoE-A-QoL questionnaire may need future adjustments and, if possible, simplifications, in order to make it even more suitable for routine use in measuring health-related QoL in adult EoE patients.

In conclusion, a valid EoE-A-QoL Spanish questionnaire is now available as a useful tool in clinical practice to specifically measure health-related QoL in adult patients with EoE. Anxiety related to disease diagnosis and choking were the most affected dimensions in the QoL of adult EoE patients. Continuous medical education, advances in research, and implementation of effective therapies may thus be the most effective ways to improve QoL in these patients.

## ACKNOWLEDGEMENTS

We would like to thank Dr. Tiffany T. Taft, PsyD, from the Center for Psychosocial Research in GI, Northwestern University Feinberg School of Medicine, for her helpful comments on the manuscript and insight in this study.

**Appendix 1. Spanish version of EoE-QoL-A Questionnaire**

*Por favor, piense en su vida durante la semana pasada (7 días) y lea los enunciados que aparecen debajo. Elija la respuesta que mejor describe su experiencia día a día con la esofagitis eosinofílica (EE).*

<i>Pregunta</i>	<i>Nada</i>	<i>Poco</i>	<i>Algo</i>	<i>Bastante</i>	<i>Mucho</i>
1. Encuentro estresante la enfermedad de EoE					
2. Tengo que tener cuidado al comer porque padezco EoE					
3. Tengo sensación de pánico o de no poder controlarme al tener dificultades para tragar					
4. Me preocupan los efectos secundarios a largo plazo causados por la medicación para la EoE					
5. A causa de la EoE, mi rutina diaria no me parece normal					
6. Me siento impotente a causa de la EoE					
7. Me pongo nervioso o me entra ansiedad antes de las comidas					
8. Me asusta no poder respirar cuando tengo dificultad para tragar					
9. Me avergüenza tener que pedir comidas especiales en los restaurantes					
10. Me preocupa tener que seguir un tratamiento para la EoE durante el resto de mi vida					
11. Tengo la sensación de que disfruto menos de mi vida por la EoE					
12. Me preocupa que nunca se identifique lo que causa mi EoE					
13. Me siento frustrado por padecer la EoE					
14. Trato de disimular mi dificultad al tragar para que el resto de la gente no se dé cuenta de lo que me ocurre					
15. Me preocupa que la EoE vaya a más o empeore					
16. Me siento frustrado al no poder comer lo que quiero por la EoE					
17. Me preocupa causar ansiedad a mi familia cuando me atraganto					
18. El hecho de que la EoE sea una enfermedad relativamente nueva me provoca ansiedad					
19. Me siento frustrado cuando la gente piensa que soy yo quien causa mis atragantamientos por comer demasiado deprisa o tomar bocados demasiado grandes					
20. Me preocupa no saber cuándo volveré a tener otro atragantamiento					
21. Lo paso mal cuando tengo que explicar la EoE a mi familia para que no se preocupen tanto					
22. Me resulta embarazoso el tener que permanecer largo rato en el baño intentando solucionar un atragantamiento					
23. Me siento aislado de los demás a causa de mi EoE					
24. Me preocupa el no poder comer nunca con normalidad por la EoE					
25. Me preocupa que cuando estoy fuera de casa no vaya a encontrar comida adecuada para mí					
26. Me preocupa comer en restaurantes por miedo a la contaminación de los alimentos					
27. Paso mucho tiempo planificando mis comidas					
28. Encuentro problemático leer las etiquetas de [los envases de] la comida y comprar en tiendas especializadas					
29. Acabo gastando más dinero en comida por la EoE					
30. Me resulta difícil encontrar productos que yo pueda comer por la EoE					



## Appendix 2. Centers participating in the study

Hospital	n (%)
Hospital General de Tomelloso	59 (34.7 %)
Hospital San Pedro de Alcántara	33 (19.4 %)
Hospital Universitario Central de Asturias	27 (15.9 %)
Hospital Universitario Río Ortega	19 (11.2 %)
Complejo Hospitalario de Navarra	13 (7.6 %)
Clínica Ruber	11 (6.5 %)
Hospital Universitario 12 Octubre	5 (2.9 %)
Hospital Viladecans	3 (1.8 %)

## REFERENCES

1. Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. *J Allergy Clin Immunol* 2011;128:3-20.
2. DeBrosse CW, Franciosi JP, King EC, Butz BK, Greenberg AB, Collins MH, et al. Long-term outcomes in pediatric-onset esophageal eosinophilia. *J Allergy Clin Immunol* 2011;128:132-8.
3. Hruz P, Straumann A, Bussmann C, Heer P, Simon HU, Zwahlen M, et al. Escalating incidence of eosinophilic esophagitis: A 20-year prospective, population-based study in Olten County, Switzerland. *J Allergy Clin Immunol* 2011;128:1349-50.
4. Arias A, Lucendo AJ. Prevalence of eosinophilic oesophagitis in adult patients in a central region of Spain. *Eur J Gastroenterol Hepatol* 2013;25:208-12.
5. Dellon ES, Jensen ET, Martin CF, Shaheen NJ, Kappelman MD. The Prevalence of eosinophilic esophagitis in the United States. *Clin Gastroenterol Hepatol* 2014;12:589-96.e1.
6. Ronkainen J, Talley NJ, Aro P, Storskrubb T, Johansson SE, Lind T, et al. Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: The population-based Kalixanda study. *Gut* 2007;56:615-20.
7. Lucendo AJ, Sanchez-Cazalilla M. Adult versus pediatric eosinophilic esophagitis: important differences and similarities for the clinician to understand. *Expert Rev Clin Immunol* 2012;8:733-45.
8. Straumann A. The natural history and complications of eosinophilic esophagitis. *Gastrointest Endosc Clin N Am* 2008;18:99-118.
9. Klennert MD. Psychological impact of eosinophilic esophagitis on children and families. *Immunol Allergy Clin North Am* 2009;29:99-107.
10. Harris RF, Menard-Katcher C, Atkins D, Furuta GT, Klennert MD. Psychosocial dysfunction in children and adolescents with eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr* 2013;57:500-5.
11. Gonzalez-Castillo S, Arias A, Lucendo AJ. Treatment of eosinophilic esophagitis: How should we manage the disease? *J Clin Gastroenterol* 2010;44:663-71.
12. Casellas F, Lopez-Vivancos J, Casado A, Malagelada JR. Factors affecting health related quality of life of patients with inflammatory bowel disease. *Qual Life Res* 2002;11:775-81.
13. Garrigues V, Ortiz V, Casanova C, Bujanda L, Moreno-Osset E, Rodríguez-Téllez M, et al. Disease-specific health-related quality of life in patients with esophageal achalasia before and after therapy. *Neurogastroenterol Motil* 2010;22:739-45.
14. Hoivik ML, Bernklev T, Moum B. Need for standardization in population-based quality of life studies: A review of the current literature. *Inflamm Bowel Dis* 2010;16:525-35.
15. Amouretti M, Le Pen C, Gaudin AF, et al. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). *Gastroenterol Clin Biol* 2006;30:241-6.
16. Casellas F, Rodrigo L, Molina-Infante J, Vivas S, Lucendo AJ, Rosinach M, et al. Transcultural adaptation and validation of the Celiac Disease Quality of Life (CD-QOL) survey, a specific questionnaire to measure quality of life in patients with celiac disease. *Rev Esp Enferm Dig* 2013;105:585-93.
17. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. *Ann Intern Med* 1993;118:622-9.
18. Testa M. Current concepts: Assessment of quality-of-life outcomes. *N Eng J Med* 1996;334:835-40.
19. Testa M. Measurement of health outcomes in treatment effectiveness evaluations: conceptual and methodological challenges. *Med Care* 2000;38(9 Supl.):II14-25.
20. Taft TH, Kern E, Keefer L, Burstein D, Hirano I. Qualitative assessment of patient-reported outcomes in adults with eosinophilic esophagitis. *J Clin Gastroenterol* 2011;45:769-74.
21. Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ, Abonia JP, et al. Quality of life in paediatric eosinophilic oesophagitis: What is important to patients? *Child Care Health Dev* 2012;38:477-83.
22. Taft TH, Kern E, Kwiatek MA, Hirano I, Gonsalves N, Keefer L. The adult eosinophilic oesophagitis quality of life questionnaire: A new measure of health-related quality of life. *Aliment Pharmacol Ther* 2011;34:790-8.
23. Bajaj S, Taft T, Keefer L, Gonsalves N, Hirano I. Validity, usability, and acceptability of the Eosinophilic Esophagitis Quality of Life scale for adults (EoE-QOL-A). *Gastroenterology* 2012;142 (Suppl 1):S-434.
24. Vilagut G, Valderas JM, Ferrer M, Garin O, López-García E, Alonso J. Interpretation of SF-36 and SF-12 questionnaires in Spain: Physical and mental components. *Med Clin (Barc)* 1986;130:726-35.
25. Broadbent E, Petrie KJ, Main J, Weinman JA. The Brief Illness Perception Questionnaire. *J Psychosom E* 2006;60:631-7.
26. Pacheco-Huergo V, Viladrich C, Pujol-Ribera E, Cabezas-Peña C, Núñez M, Roura-Olmeda P, et al. Perception in chronic illnesses: Linguistic validation of the revised Illness Perception Questionnaire and the Brief Illness Perception Questionnaire for a Spanish population. *Aten Primaria* 2012;44:280-7.
27. Tejero A, Guimerá EM, Farré JM, Peri JM. Uso clínico del HAD (Hospital Anxiety and Depression Scale) en población psiquiátrica: un estudio de su sensibilidad, fiabilidad y validez. *Rev Depto Psiquiatría Facultad de Med Barna* 1986;13:233-8.
28. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. *J Clin Epidemiol* 2007;60:34-42.